NCT01073540View on ClinicalTrials.gov

Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension

PHASE1CompletedINTERVENTIONAL

Enrollment

26

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions

Anti-Infective Agents

Interventions

DRUG

Cephalexin suspension (Optocef, BAYO5448)

Single dose of 500 mg / 10 mL

DRUG

Cephalexin suspension (Keflex)

Single dose of 500 mg / 20 mL

Trial Locations (1)

58256

Morelia

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Corporación Bonima S.A. de C.V.

INDUSTRY

lead

Bayer

INDUSTRY